Forimtamig
- Generic Name
- Forimtamig
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1
Active, not recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT06055075
- Locations
- 🇦🇺
Princess Alexandra Hospital Woolloongabba, Woolloongabba, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦Hamilton Health Sciences, Hamilton, Ontario, Canada
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT04557150
- Locations
- 🇦🇺
Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
🇧🇪UZ Gent, Gent, Belgium
🇩🇰Rigshospitalet, København Ø, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath